Correspondence 0001493152-24-036982 from Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc.
Date: Sept. 18, 2024 · CIK: 0001857044 · Accession: 0001493152-24-036982
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282069
Letter
September 18, 2024
Via EDGAR Transmission
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, N.E.
Washington, D.C. 20549
Attention: Lauren Hamill
Re: Indaptus Therapeutics, Inc.
Registration Statement on Form S-1
Originally Filed September 12, 2024
Registration No. 333-282069
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on Friday, September 20, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Indaptus Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Elisabeth M. Martin of Latham & Watkins LLP at (617) 948-6018 to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely
yours,
Indaptus
Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
September
18, 2024
Via
EDGAR Transmission
United
States Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Lauren Hamill
Re:
Indaptus
Therapeutics, Inc.
Registration
Statement on Form S-1
Originally
Filed September 12, 2024
Registration
No. 333-282069
Ladies
and Gentlemen:
In
accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby
request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on Friday,
September 20, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Indaptus Therapeutics,
Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Elisabeth M. Martin
of Latham & Watkins LLP at (617) 948-6018 to provide notice of effectiveness, or if you have any other questions or concerns regarding
this matter.
Sincerely
yours,
Indaptus
Therapeutics, Inc.
By:
/s/
Nir Sassi
Nir
Sassi
Chief
Financial Officer
cc:
Peter
N. Handrinos, Latham & Watkins LLP